Related Experiment Video

Updated: Dec 30, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth

Jungjoong Hwang1, Insuk Song1, Kwangho Lee2

  • 1College of Pharmacy, Kangwon National University, 1 Kangwondaehak-gil, Chuncheon, Gangwon-do, 24341, Republic of Korea.

Investigational New Drugs
|January 21, 2020
PubMed

Insights

The anaplastic lymphoma kinase (ALK) inhibitor KRCA-0008 effectively suppressed proliferation and induced apoptosis in anaplastic large-cell lymphoma (ALCL) cells. This ALK inhibitor shows therapeutic potential for ALCL patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic lymphoma kinase (ALK) is crucial for nervous system development.
  • Aberrant ALK activation, through genetic alterations, drives various cancers like ALCL, non-small cell lung cancer, and neuroblastoma.
  • NPM-ALK fusion protein is a key oncogenic driver in ALCL.

Purpose of the Study:

  • To evaluate the anti-cancer activity of the novel ALK inhibitor, KRCA-0008.
  • To assess the efficacy of KRCA-0008 in anaplastic large-cell lymphoma (ALCL) models.
  • To investigate the molecular mechanisms underlying KRCA-0008's action.

Main Methods:

  • Utilized ALCL cell lines expressing NPM-ALK.
  • Assessed KRCA-0008's effects on cell proliferation, survival, cell cycle, and apoptosis.
  • Analyzed downstream signaling pathways including STAT3, Akt, and ERK1/2.
  • Evaluated in vivo anti-tumor activity using a Karpas-299 tumor xenograft mouse model.

Main Results:

  • KRCA-0008 significantly inhibited proliferation and survival of NPM-ALK-positive ALCL cells.
  • The drug induced G0/G1 cell cycle arrest and apoptosis.
  • Downstream signaling pathways (STAT3, Akt, ERK1/2) were effectively blocked.
  • Oral administration of KRCA-0008 markedly suppressed tumor growth in vivo.

Conclusions:

  • KRCA-0008 demonstrates potent anti-cancer activity against NPM-ALK-positive ALCL.
  • The findings support KRCA-0008's potential as a therapeutic agent for ALCL patients.
  • KRCA-0008 is a valuable tool for further research into ALK signaling pathways.
Keywords:
Anaplastic large cell lymphoma (ALCL)Anaplastic lymphoma kinase (ALK) inhibitorApoptosisCell cycle arrestKRCA-0008

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.8K
Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

23.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K